Your AI-Trained Oncology Knowledge Connection!
Postsurgery complications are infrequent among breast cancer patients undergoing surgery with reconstruction; however, according to a large database study, the rates of certain complications, including reoperation, blood transfusion, and implant loss, are higher with bilateral mastectomy versus unilateral mastectomy.
The 2nd Annual Giants of Cancer Careâ„¢ Awards were presented at a ceremony held on May 30 in Chicago. The event recognized 16 oncology heroes whose groundbreaking contributions to the field have improved the lives of patients with cancer.
Combining panobinostat (LBH589) with bortezomib and dexamethasone delayed disease progression by 3.9 months over bortezomib and dexamethasone alone in patients with relapsed or relapsed and refractory multiple myeloma.
Frontline therapy with bevacizumab (Avastin) or cetuximab (Erbitux) combined with either FOLFOX or FOLFIRI yielded a comparable survival benefit of approximately 29 months in patients with KRAS wild-type metastatic colorectal cancer
Adding the VEGFR-2 inhibitor ramucirumab to standard docetaxel improved overall survival by 1.4 months versus docetaxel alone in patients with advanced non–small cell lung cancer.
The dosing frequency of zoledronic acid can be reduced by 67% without compromising efficacy and safety in women with breast cancer and bone metastases.
Two recently published clinical studies demonstrated a strong association between higher levels of vitamin D and improved outcomes among patients with various cancers.
Despite evidence supporting its efficacy, chemotherapy is not routinely administered to patients with muscle-invasive bladder cancer.
In December 2013, the US Preventive Services Task Force (USPSTF) recommended that asymptomatic, high-risk individuals receive annual screening for lung cancer with low-dose computed tomography (LDCT).
At the 18th Annual International Congress on Hematologic Malignancies, Anas Younes, MD, sat down with Oncology & Biotech News to discuss trends in the management of hematologic malignances.
New models have emerged for examining novel breast cancer treatments in the neoadjuvant setting that avoid the lengthy process of standard, large adjuvant trials.
Over the past few decades, the optimal margin width for minimizing recurrence after breast-conserving surgery (BCS; lumpectomy) has been a topic of much debate
An analysis of phase III, second-line data has shown that RAS mutations beyond KRAS exon 2 are negative predictive biomarkers for the EGFR-inhibitor panitumumab in metastatic colorectal cancer.
Molecular testing and novel therapies have revolutionized the management of metastatic melanoma in recent years.
Over the past year, there has been a multitude of exciting developments in the treatment of patients with non-small cell lung cancer
Although crizotinib (Xalkori) is highly effective in treating patients with advanced ALK-positive non–small cell lung cancer (NSCLC), most patients develop resistance to the drug.
Salvage therapy combining the novel heat shock protein 90 inhibitor ganetespib with docetaxel significantly improved overall survival in some patients with non–small cell lung cancer.
Bevacizumab combined with either of two chemotherapy backbones improved overall survival by 3.7 months versus chemotherapy alone in patients with advanced cervical cancer.
Frontline cetuximab plus FOLFIRI chemotherapy improved overall survival by 3.7 months versus bevacizumab plus FOLFIRI in patients with KRAS wild-type metastatic colorectal cancer.
Active surveillance for low-grade prostate cancer has long been considered the elusive "holy grail" for mitigating the overtreatment effect of PSA screening.
The mortality rate from prostate cancer has declined significantly in the past few decades; however, there is much debate over how much PSA screening contributed to that decline.
Susan F. Slovin, MD, PhD, from Memorial Sloan-Kettering Cancer Center, provides an overview of the most promising immunotherapeutic follow-ups to sipuleucel-T in prostate cancer.
Combining the checkpoint antibodies ipilimumab and nivolumab led to deep tumor regression in approximately one-third of patients with advanced melanoma.
Discussion with Edith Perez, MD, about key research presented at SABCS, ongoing developments in breast cancer treatment, and the current focal areas of her research.
Adjuvant chemotherapy with the oral fluoropyrimidine S-1 improved survival versus standard postoperative gemcitabine in Asian patients with pancreatic cancer, according to an interim analysis from a phase III trial conducted in Japan.
Nab-paclitaxel might offer some hope for patients with advanced urothelial cancer, an area that has lagged behind the rapid growth in available therapies for other genitourinary cancers.
Over the past decade, the availability of new agents with varying mechanisms of action has greatly enhanced the treatment landscape in castration-resistant prostate cancer.
The mental toll and stress of a breast cancer diagnosis might factor into the cognitive impairment experienced during chemotherapy treatment, commonly referred to as "chemo brain."
Long-term follow-up results showed that the hypofractionated regimens were as effective as the 50-Gy standard in women with early-stage breast cancer.
Eight-year follow-up data from the phase III HERA trial has confirmed that 1-year of adjuvant trastuzumab should remain the treatment standard in women with HER2-positive early-stage breast cancer.
